Fundz
An acquisition means integration work is about to be scoped. Fundz scores the company against what you sell, and says why it matched.See it live →

Dimerix Partners for Drug Development, Secures Over $80 Million in Licensing Deals.

Sep 17, 2026•about 4 hours ago

Contract Type

partnership

MelbourneBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Dimerix has achieved five regional licensing agreements for its kidney drug candidate DMX-200, securing more than $80 million upfront. The partnerships not only provide non-dilutive funding but also enhance capabilities and growth potential for the company's clinical programs.

Company Information

Company

Dimerix Limited

Location

Melbourne, Victoria, Australia

About

Dimerix is a clinical-stage biopharmaceutical company, with a portfolio of drug candidates for inflammatory diseases, including kidney and respiratory diseases. Dimerix' lead candidate is in Phase 3 clinical trials for a rare type of kidney disease. Dimerix encourages collaboration and is well positioned to discuss partnering and product development.

Related People

Suggested for you
Nina
Senior decision-maker at this company
••••••••@••••••••

See Nina's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for Dimerix Limited's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Dimerix Limited signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 285,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.